These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29170395)

  • 1. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
    Berenjeno IM; Piñeiro R; Castillo SD; Pearce W; McGranahan N; Dewhurst SM; Meniel V; Birkbak NJ; Lau E; Sansregret L; Morelli D; Kanu N; Srinivas S; Graupera M; Parker VER; Montgomery KG; Moniz LS; Scudamore CL; Phillips WA; Semple RK; Clarke A; Swanton C; Vanhaesebroeck B
    Nat Commun; 2017 Nov; 8(1):1773. PubMed ID: 29170395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating breast cancer by PIK3CA mutation.
    Miller TW
    Breast Cancer Res; 2012 Feb; 14(1):301. PubMed ID: 22315990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
    Cufí S; Corominas-Faja B; Lopez-Bonet E; Bonavia R; Pernas S; López IÁ; Dorca J; Martínez S; López NB; Fernández SD; Cuyàs E; Visa J; Rodríguez-Gallego E; Quirantes-Piné R; Segura-Carretero A; Joven J; Martin-Castillo B; Menendez JA
    Oncotarget; 2013 Sep; 4(9):1484-95. PubMed ID: 23986086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.
    Spangle JM; Von T; Pavlick DC; Khotimsky A; Zhao JJ; Roberts TM
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24427-24433. PubMed ID: 32929011
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA
    Liu XL; Liu JL; Xu YC; Zhang X; Wang YX; Qing LH; Guo W; Ding J; Meng LH
    Int J Cancer; 2019 Aug; 145(3):817-829. PubMed ID: 30671946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
    Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
    Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PIK3CA gene is mutated with high frequency in human breast cancers.
    Bachman KE; Argani P; Samuels Y; Silliman N; Ptak J; Szabo S; Konishi H; Karakas B; Blair BG; Lin C; Peters BA; Velculescu VE; Park BH
    Cancer Biol Ther; 2004 Aug; 3(8):772-5. PubMed ID: 15254419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
    Liu P; Cheng H; Santiago S; Raeder M; Zhang F; Isabella A; Yang J; Semaan DJ; Chen C; Fox EA; Gray NS; Monahan J; Schlegel R; Beroukhim R; Mills GB; Zhao JJ
    Nat Med; 2011 Aug; 17(9):1116-20. PubMed ID: 21822287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
    Kadota M; Sato M; Duncan B; Ooshima A; Yang HH; Diaz-Meyer N; Gere S; Kageyama S; Fukuoka J; Nagata T; Tsukada K; Dunn BK; Wakefield LM; Lee MP
    Cancer Res; 2009 Sep; 69(18):7357-65. PubMed ID: 19706770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.
    Dong L; Meng F; Wu L; Mitchell AV; Block CJ; Zhang B; Craig DB; Jang H; Chen W; Yang Q; Wu G
    Int J Oncol; 2017 Oct; 51(4):1320-1330. PubMed ID: 28902361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
    Menteş M; Karakuzulu BB; Uçar GB; Yandım C
    Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.